Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $11.6 million.

  • Pulse Biosciences' Non-Current Assets fell 810.64% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.2 million, marking a year-over-year decrease of 713.34%. This contributed to the annual value of $13.0 million for FY2024, which is 589.47% down from last year.
  • Per Pulse Biosciences' latest filing, its Non-Current Assets stood at $11.6 million for Q3 2025, which was down 810.64% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Non-Current Assets ranged from a high of $18.6 million in Q1 2021 and a low of $11.6 million during Q3 2025
  • For the 5-year period, Pulse Biosciences' Non-Current Assets averaged around $14.8 million, with its median value being $14.3 million (2023).
  • Over the last 5 years, Pulse Biosciences' Non-Current Assets had its largest YoY gain of 2057.75% in 2021, and its largest YoY loss of 2705.5% in 2021.
  • Pulse Biosciences' Non-Current Assets (Quarter) stood at $13.8 million in 2021, then increased by 13.77% to $15.7 million in 2022, then fell by 12.1% to $13.8 million in 2023, then decreased by 5.89% to $13.0 million in 2024, then decreased by 10.78% to $11.6 million in 2025.
  • Its Non-Current Assets stands at $11.6 million for Q3 2025, versus $12.1 million for Q2 2025 and $12.5 million for Q1 2025.